Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Maze Therapeutics, Inc.NASDAQ: MAZE
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$22.9M, compared with -$32.1M a year earlier. Trailing-twelve-month EBITDA was -$119.51M.
Context
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 10 analysts of -$107.12M (+16.8%) for the fiscal year ending Dec 2026, a step up from the -327.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$22.9M+32.8% QoQ
- Last fiscal yearDec 2025
- -$128.72M-327.0% YoY
- LTMMar 2026
- -$119.51M-312.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +28.7% | -28.2% | -56.8 pp |
| 1 year | -327.0% | +16.8% | +343.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (128.72M) USD
- Year-over-year change
- -327.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (128.72M) | -327.0% |
| FY2024 | 2024-12-31 | 56.7M | +158.9% |
| FY2023 | 2023-12-31 | (96.33M) | +13.3% |
| FY2022 | 2022-12-31 | (111.12M) | — |
EBITDA vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -312.9% is the 7th highest of 8, against a peer median of -28.4%.
- EBITDA amounts to 597.6% of revenue for MAZE, versus a peer median of 38.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $173.52M USD | -79.4% | — | 17.2% | |
| LTM Mar 2026 | -$25.52M USD | +9.6% | — | 6.0% | |
| LTM Mar 2026 | -$35.03M USD | -30.1% | — | — | |
SEPNSepterna, Inc. | LTM Sep 2026 | -$57.07M USD | +24.4% | — | 59.3% |
BIOABioAge Labs, Inc. | LTM Mar 2026 | -$89.21M USD | -28.4% | — | 864.8% |
| LTM Sep 2026 | -$106.58M USD | -372.0% | — | 16.4% | |
| LTM Mar 2026 | -$119.51M USD | -312.9% | — | 597.6% | |
| FY2025 | -€128.15M EUR | +23.0% | — | 2858.6% | |
| Peer median (excluding MAZE) | — | -28.4% | — | 38.2% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 167.5M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 2.4M |
| Gross Profit | 0 | 0 | 167.5M | (2.4M) |
| Gross Margin | — | — | 100.0% | — |
| Research & Development | 88.19M | 73.95M | 83.5M | 108.45M |
| Selling, General & Admin | 22.83M | 24.61M | 26.42M | 34.45M |
| Operating Expenses | 111.03M | 98.55M | 109.91M | 140.5M |
| Depreciation & Amortization | 3.82M | 4.09M | 3.3M | 2.4M |
| EBITDA | (111.12M) | (96.33M) | 56.7M | (128.72M) |
| EBITDA Margin | — | — | 33.9% | — |
| Operating Income | (111.03M) | (98.55M) | 57.59M | (142.9M) |
| Operating Margin | — | — | 34.4% | — |
| Interest Income | 2.03M | 1.97M | 4.65M | 11.78M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (3.91M) | (1.86M) | (4.18M) | 11.78M |
| Income Before Tax | (114.94M) | (100.42M) | 53.4M | (131.12M) |
| Pre-Tax Margin | — | — | 31.9% | — |
| Income Tax Expense | 0 | 0 | 1.17M | 0 |
| Net Income | (114.94M) | (100.42M) | 52.23M | (131.12M) |
| Net Margin | — | — | 31.2% | — |
| EPS (Basic) | (2.63) | (2.29) | 0.08 | (3.05) |
| EPS (Diluted) | (2.63) | (2.29) | 0.08 | (3.05) |
| Weighted Avg Shares | 43.78M | 43.78M | 43.8M | 42.98M |
| Weighted Avg Shares (Diluted) | 43.78M | 43.78M | 43.8M | 42.98M |
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.